title: [Tumor lysis syndrome with symptomatic hyperuricemia after a first chemotherapeutic treatment of undifferentiated carcinoma of the cavum].
authors.forename: N
authors.initials: N
authors.lastname: Penel
authors.forename: H
authors.initials: H
authors.lastname: Kouto
authors.forename: C
authors.initials: C
authors.lastname: Ala-Eddine
authors.forename: M
authors.initials: M
authors.lastname: Degardin
mesh_terms: D000328:Adult; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage / Q000009:adverse effects*; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage / Q000009:adverse effects*; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D001761:Bleomycin / Q000008:administration & dosage / Q000009:adverse effects*; D002277:Carcinoma / Q000000981:diagnostic imaging / Q000188:drug therapy*; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects*; D015251:Epirubicin / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D008297:Male; D009303:Nasopharyngeal Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy*; D013997:Time Factors; D014057:Tomography, X-Ray Computed; D015275:Tumor Lysis Syndrome / Q000175:diagnosis / Q000209:etiology*; D014527:Uric Acid / Q000097:blood*
chemical_list: D000903:Antibiotics, Antineoplastic; D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; D001761:Bleomycin; D014527:Uric Acid; D015251:Epirubicin; D002945:Cisplatin
vernacular_title: Syndrome de lyse tumorale avec hyperuricémie symptomatique après une première cure de chimiothérapie pour carcinome indifférencié du cavum.